Physician profile
Prema Siva
NPI 1699722009
$3,442.56
in general payments reported to CMS, 2019-2025
29 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $296 · 2021: $580 · 2022: $869 · 2023: $562 · 2024: $751 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $697.46 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $392.11 | 2021-2024 | |
| Lilly USA, LLC | $353.37 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $258.85 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $184.59 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.42 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $166.53 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $152.40 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $149.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $111.36 | 2020-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Sanofi-Aventis U.S. LLC | $109.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $83.47 | 2019-2024 | Shingrix, Arexvy |
| Optinose US, INC. | $78.69 | 2021-2022 | |
| Medtronic, INC. | $77.83 | 2022 | |
| Amgen INC. | $73.01 | 2019-2025 | Repatha, Otezla, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $67.94 | 2020-2021 | |
| Sanofi Pasteur INC. | $44.12 | 2023-2024 | |
| Dexcom, INC. | $41.89 | 2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $38.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.56 | 2021-2022 | |
| Abbvie INC. | $22.87 | 2024 | |
| Daiichi Sankyo INC. | $20.65 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $20.26 | 2024 | Givlaari |
| Watermark Medical, INC. | $18.54 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.34 | 2022 | |
| Horizon Therapeutics Plc | $16.53 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.85 | 2024 | Caplyta |
| Nevro Corp. | $13.20 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prema Siva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.